Maryland's Proton Pioneer: A Decade of Precision Cancer Treatment

BALTIMORE, MD – February 23, 2026 – Ten years ago today, the landscape of cancer care in the Mid-Atlantic region changed permanently. The Maryland Proton Treatment Center (MPTC) opened its doors, becoming the first facility to offer this highly advanced form of radiation therapy in Maryland, Washington D.C., and Northern Virginia. A decade later, the center is celebrating a milestone built on treating over 6,000 patients, pioneering clinical research, and, perhaps most significantly, forging a unique path toward making cutting-edge care more accessible.

When MPTC was established in 2016, it was one of only 14 such centers in the entire country. Today, as it honors its staff and the thousands of patients who have walked its halls, it stands as a veteran institution in a field that has grown to nearly 50 centers nationwide. Its story is one of not just technological adoption, but of a sustained effort to solve the persistent healthcare challenges of cost and access.

A New Era of Precision in Cancer Treatment

At the core of MPTC's mission is the technology itself: proton therapy. Unlike traditional photon radiation, which uses X-rays that pass through the body and exit on the other side, proton therapy uses charged particles that can be stopped precisely at a tumor's location. This allows oncologists to deliver a powerful, concentrated dose of radiation directly to cancerous cells while significantly sparing surrounding healthy tissues and organs.

The clinical implications of this precision are profound. Research has consistently shown that patients undergoing proton therapy experience fewer and less severe side effects. One major comparative study found that patients receiving proton therapy had a two-thirds reduction in the relative risk of severe side effects—those serious enough to require hospitalization—within 90 days of treatment compared to those receiving traditional X-ray therapy. For patients, this can mean a better quality of life during an arduous treatment journey, with less nausea, fatigue, and damage to critical functions like swallowing. The benefit is particularly crucial for pediatric patients, whose developing bodies are more vulnerable to the long-term consequences of radiation, including the risk of secondary, radiation-induced cancers later in life.

MPTC enhanced this capability from day one by implementing cutting-edge pencil beam scanning. This advanced technique essentially “paints” the tumor with a proton beam layer by layer, offering an even greater degree of conformity and precision than older proton therapy methods. This focus on minimizing collateral damage has allowed MPTC to treat complex cases, including tumors near sensitive structures like the brain stem, spinal cord, and heart, as well as patients who require re-irradiation in an area that has previously received radiation.

Redefining Access: The 'Cost-Neutral' Revolution

While the clinical benefits of proton therapy are compelling, its adoption has historically been hampered by one major obstacle: cost. The machinery is massive, complex, and carries a nine-figure price tag for construction and installation, leading to higher treatment costs that insurers are often reluctant to cover.

This is where MPTC charted a different course. From its inception, the center established a “cost-neutral” rate structure, billing insurance companies the same amount for a course of proton therapy as they would for conventional, photon-based radiation therapy. This bold financial model directly confronts the primary barrier to patient access.

“Because of this affordable cost structure, MPTC currently has an insurance approval rate of above 90%,” the center noted in its anniversary announcement. This figure, largely consistent with independent reports over the years, stands in stark contrast to the lengthy and often unsuccessful battles many patients at other facilities face when seeking insurance authorization. By removing the cost variable from the clinical decision-making process between provider and payer, MPTC has made proton therapy a viable option for thousands of patients who might otherwise have been denied access.

This model has not only benefited the more than 90% of its patients who are Maryland residents but has also served as a case study for the nation on how to potentially bridge the gap between medical innovation and practical affordability.

A Decade of Data and Discovery

MPTC’s impact extends well beyond its individual patient success stories. Through its affiliation with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), an NCI-designated institution, and the University of Maryland Department of Radiation Oncology, the center is deeply embedded in the world of academic medicine.

This partnership has transformed the Baltimore facility into a hub for research and education. Over the past decade, MPTC has participated in 53 clinical trials and enrolled more than 2,544 patients into the Proton Collaborative Group (PCG) national registry. This contribution of data is vital for building the large-scale evidence base needed to further validate proton therapy’s benefits across a wider range of cancer types. The center’s oncologists, who are faculty at the University of Maryland School of Medicine, are actively leading research, including clinical trials evaluating proton therapy for aggressive brain tumors like glioblastoma.

Furthermore, the center has become a global training ground, having educated hundreds of medical professionals from around the world on the intricacies of proton therapy. Its unique position as a facility offering both proton and thermal therapies under one roof also points to an innovative, multi-modal approach to cancer treatment.

Navigating a Shifting Landscape

While MPTC remains the only proton center in Maryland, the regional landscape has evolved since its pioneering debut in 2016. Competing centers have since opened in Washington D.C., including at MedStar Georgetown University Hospital and the Johns Hopkins Sibley Memorial Hospital, giving patients in the broader metropolitan area more options. This regional growth mirrors a national and global trend, with the proton therapy market projected to expand significantly in the coming years, driven by rising cancer rates and increasing awareness of precision medicine.

Despite this growth, the industry continues to face challenges, primarily the high capital costs of new facilities and ongoing debates with some payers over the necessity of proton therapy for certain common cancers. However, as technology improves, with advancements in more compact and efficient systems, and as more long-term data from centers like MPTC emerges, the case for proton therapy continues to strengthen.

After ten years of service, the Maryland Proton Treatment Center's legacy is twofold: it successfully brought a paradigm-shifting technology to its region while simultaneously challenging the economic status quo that often keeps such advancements out of reach for ordinary patients. As it moves into its second decade, its experience provides a crucial roadmap for the future of advanced cancer care.